OncoMatch/Clinical Trials/NCT06921928
Study for AZD4360 in Participants With Advanced Solid Tumours
Is NCT06921928 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies AZD4360 for gastric cancer.
Treatment: AZD4360 — The purpose of this study is to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD4360 in adult participants with locally advanced or metastatic solid tumours selected for expression of CLDN18.2.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Gastric Cancer
Esophageal Carcinoma
Cholangiocarcinoma
Pancreatic Cancer
Biomarker criteria
Required: CLDN18 positive expression
documented positive CLDN18.2 expression
Required: HER2 (ERBB2) positive (3+ by IHC or 2+ by IHC and positive by in situ hybridisation) or indeterminate
Human Epidermal Growth Factor Receptor 2 (HER2) positive (3+ by IHC or 2+ by IHC and positive by in situ hybridisation) or indeterminate G/GEJC participants
Disease stage
Metastatic disease required
Histologically confirmed advanced or metastatic... At least one measurable lesion according to RECIST v1.1.
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Lab requirements
Blood counts
Adequate organ and marrow function, as defined by protocol.
Kidney function
Adequate organ and marrow function, as defined by protocol.
Liver function
Adequate organ and marrow function, as defined by protocol.
Adequate organ and marrow function, as defined by protocol.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · Santa Monica, California
- Research Site · Providence, Rhode Island
- Research Site · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06921928 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require CLDN18?
Yes, CLDN18 positive expression is a required biomarker for enrollment.
Does this trial require ERBB2?
Yes, ERBB2 positive (3+ by IHC or 2+ by IHC and positive by in situ hybridisation) or indeterminate is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 130 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify